LENZ Therapeutics
LENZ
51 hedge funds and large institutions have $981M invested in LENZ Therapeutics in 2021 Q2 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8.21% more ownership
Funds ownership: 0% → 8.21% (+8.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$185M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$93.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$67.1M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$53.5M |
| 5 |
VA
VR Adviser
New York
|
+$40.1M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$871 | +5 | New |
|
LENZ Hedge Fund Activity: Q2 2021 in Review
51 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2021, worth a combined $981M.
Buyers outnumbered sellers: 51 funds opened new LENZ positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Samsara BioCapital, opening a new position worth an estimated $185M.
- 51 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $981M of LENZ Therapeutics stock for Q2 2021.
- 51 funds opened new LENZ Therapeutics positions in Q2 2021 and 0 closed out, a net change of +51 holders.
- The largest LENZ Therapeutics buyer in Q2 2021 was Samsara BioCapital, an estimated $185M added.
Based on aggregated 13F filings for Q2 2021.